Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can reminiscing help? study tests life review for cancer patients with mild memory loss

NCT ID NCT05200572

Symptom relief Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a telehealth program called Dyadic Life Review (DLR) for older adults (65+) with advanced cancer and mild cognitive impairment, along with their caregivers. The program involved 8 weekly video sessions where patients and caregivers shared memories from different life stages. The main goal was to see if the program was feasible and acceptable, not to measure effectiveness. Out of 42 people approached, 38 agreed to participate, and most who completed the program found it acceptable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dyadic Life Review (DLR) - a structured reminiscence therapy delivered via video-conferencing
What this could lead to
If successful, this approach could offer a way to improve emotional well-being and reduce loneliness for older cancer patients with memory issues and their caregivers.
What could go wrong
This is a very small feasibility study (38 participants) with no control group, so results may not apply broadly. The intervention is time-intensive (8 sessions) and may not be practical for all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

38 people

The number who actually took part.

Started

Mar 2022

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient Inclusion Criteria: * Age ≥ 65 * Able to provide informed consent. All patients will be assessed using the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) 56 - a score \>14.5 will define ability to independently provide informed consent. * Eligible patients have Stage III or IV cancer of any type * Additionally, at least 20 patients will have a will have a high likelihood of MCI based on screening score of \<26 on the Montreal Cognitive Assessment (MoCA) within their eRecord chart. * Able to read and understand English Patient Exclusion Criteria: * Patients scoring \<14.5 on the UBACC * Unable to identify caregiver to participate in study Caregiver Inclusion Criteria: * One caregiver for each patient will be eligible and must be chosen by the patient. For the purposes of this study, a caregiver is defined as a valued and trusted person in a patient's life who is supportive in health care matters by providing valuable social support and/or direct assistive care. * Caregivers will be selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters;" patients who cannot identify such a person ("caregiver") will remain eligible for the study. * Age 50 or older * Ability to provide consent * Proficient in English Caregiver Exclusion Criteria * Caregivers unable to understand the consent form due to cognitive, health or sensory impairment will be excluded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer, advanced are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Cognitive Dysfunction neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer, advanced Cognitive impairment, mild

Contacts and locations

Locations

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.